India, March 6 -- Medicus Pharma Ltd. (MDCX) Thursday announced positive results from the interim analysis of Phase 2 study of SKNJCT-003 to non-invasively treat basal cell carcinoma of the skin (BCC). The interim analysis showed that the study is trending positively with a proportion of subjects with complete clinical clearance of more than 60 percent. Further, the drug candidate was well tolerated, with no dose limiting toxicities, or serious adverse events.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....